330786-34-0

Basic information

• Product Name: 5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)-
• CAS NO: 330786-34-0
• Molecular Formula: C14H14ClN3O3S
• Molecular Weight: 339.802
• Mol File: 330786-34-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)-(330786-34-0)
• EPA Substance Registry System: 5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)-(330786-34-0)

Safety Data

• Hazardous Substances Data: 330786-34-0(Hazardous Substances Data)

Usage

Description

5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)is a chemical compound with a pyrimidinecarboxylic acid core structure, featuring a substituted amino group and a methylthio group. The presence of chloro and methoxy substituents on the phenyl ring indicates potential interactions with biological targets, such as receptors or enzymes. This makes it a promising candidate for drug development and further investigation in medicinal chemistry and pharmaceutical research.

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)is used as a potential drug candidate for the development of new medications due to its unique structure and functional groups that may interact with biological targets, such as receptors or enzymes.
Used in Medicinal Chemistry Research:
5-Pyrimidinecarboxylic acid,
4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)is utilized in medicinal chemistry research to explore its potential interactions with biological targets and to investigate its efficacy and safety in treating various diseases or conditions.
Used in Drug Development:
5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)is employed in drug development processes to create new pharmaceuticals that can target specific receptors or enzymes, potentially leading to more effective treatments for various health issues.

Upstream product

• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 41965-95-1 (3-chloro-4-methoxyphenyl)methylamine hydrogen chloride 
• 115514-77-7 (3-chloro-4-methoxyphenyl)methanamine 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 330785-81-4 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-2-(methylsulfanyl)pyrimidine-5-carboxylate 

Downstream Products

• 330784-22-0 (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(pyridin-2-ylmethyl)carbamoyl]pyrimidine 
• 330784-47-9 avanafil 
• 372113-63-8 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyridylmethyl)carbamoyl]pyrimidine 

Relevant articles and documents

Method for synthesizing avanafil impurities

The invention discloses a method for synthesizing avanafil impurities, which belongs to the field of drug synthesis and has the advantages of reasonable process design, strong operability and mild reaction conditions. The preparation method comprises the following steps: A. hydrolyzing 4-(3-chlorine-4-methoxy phenylamino)-5-ethoxy carbonyl-2-methylthio pyrimidine I serving as a raw material in the presence of alkali to obtain a compound II; B, condensing the compound II and 2-aminomethylpyrimidine hydrochloride III under an alkaline condition to obtain a compound IV; C, oxidizing the compound IV in the presence of an oxidant to obtain a compound V; and D, reacting the compound V under an alkaline condition to obtain the avanafil impurity VI. According to the avanafil impurity prepared by the method, the impurity spectrum of avanafil is perfected, an important basis is provided for quality research of avanafil, and the safety of avanafil is further improved through research and control of the impurity.

A process for the preparation of atorvastatin that non-intermediate and its preparation method

The invention provides a novel intermediate IV which is used for preparation of avanafil. The intermediate has a general formula IV as described in the specification; and in the general formula IV, R represents a C1-20 alkylsulfinyl group or a C1-20 alkylsulfonyl group. The intermediate has high purity, is suitable for industrial production and can be subjected to a one-step chemical reaction to prepare avanafil. The invention also provides a preparation method for the intermediate and a method for preparing avanafil from the intermediate.

8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors

A novel series of highly selective phosphodiesterase 5 (PDE5) inhibitors was found. 8H-Pyrido[2,3-d]pyrimidin-7-one derivatives bearing an (S)-2-(hydroxymethyl)pyrrolidin-1-yl group at the 2-position and a 3-chloro-4-methoxybenzyl group at the 8-position